Noven Pharmaceuticals Inc.

Jeffrey Eisenberg serves as Noven’s Executive Vice President and as President of Novogyne Pharmaceuticals, Noven's joint venture with Novartis Pharmaceuticals Corporation. He has been part of Noven’s senior management team since 1998, having previously served as Senior Vice President – Strategic Alliances, and as General Counsel. From 1995 through 1998, he served as Associate General Counsel and then as Acting General Counsel of IVAX Corporation. Prior to IVAX, he was a lawyer in the corporate securities department of the law firm of Steel Hector & Davis.

Mr. Brandt was appointed to Noven’s board of directors and to the offices of President & Chief Executive Officer of Noven in April 2008. He spent 28 years at Pfizer, Inc., the world's leading research-based pharmaceutical company. Until early 2007, he served as Pfizer’s President – U.S. Pharmaceuticals Operations, where he oversaw Pfizer’s U.S. pharmaceuticals organization. Previously, he led Pfizer’s Latin American Pharmaceuticals Operations, as well as the following Pfizer Worldwide Pharmaceuticals functions: Finance, Information Technology, Planning and Business Development. He also directed the operations of Pfizer's care management subsidiary, Pfizer Healthcare Solutions.

Mr. Yetter serves as Noven's non-executive Chairman of the Board. He was Chief Executive Officer of Verispan LLC (health care information) from September 2005 through August 2008. From November 2004 to September 2005, he served as the Chief Executive Officer of Odyssey Pharmaceuticals, Inc., the specialty pharmaceutical division of Pliva d.d. From 2003 to 2005, he served on the Advisory Board of Alterity Partners (mergers and acquisition advisory firm). From September 2000 to June 2003, Mr. Yetter served as Chairman and Chief Executive Officer of Synavant Inc. (pharmaceutical marketing/technology services). From 1999 to 2000, Mr. Yetter served as Chief Operating Officer at IMS Health, Inc. (information services for the healthcare industry). From 1997 to 1999, he served as President and Chief Executive Officer of Novartis Pharmaceuticals Corporation (pharmaceuticals). From 1994 to 1997, he served as President and Chief Executive Officer of Astra Merck, Inc. (pharmaceuticals). From 1991 to 1994, Mr. Yetter served as General Manager and then President of Astra Merck, a division of Merck & Co. Mr. Yetter serves on the board of directors of EpiCept Corporation (pharmaceuticals), Synvista Therapeutics, Inc. (pharmaceuticals) and InfuSystem Holdings, Inc. (infusion services).

Diane Barrett is Vice President and Chief Financial Officer. From August 2000 to May 2003, she served as Vice President – Finance and Treasurer. She is a CPA with over 20 years finance and accounting experience. Prior to joining Noven, she served as Vice President and Chief Financial Officer of Bionumerik Pharmaceuticals, Inc., which specializes in mechanism-based drug discovery. Before Bionumerik, she served in various senior finance roles at Cordis Corporation, including Treasurer and Director of Finance.

Dr. Eduardo G. Abrao joined Noven in September 2003 as Vice President – Clinical Development & Chief Medical Officer. Prior to joining Noven, he served as Vice President of Regulatory Affairs & Drug Safety at Berlex Laboratories. From 1996 to 2002, he served Otsuka America Pharmaceutical in a number of leadership roles including Executive Vice President of Regulatory & Medical Affairs and as President & Chief Operating Officer. From 1989 to 1996, he served Marion Merrell Dow in various medical and clinical affairs roles.

Juan Mantelle has been with Noven since March 1990 and, since June 2000, has served as Vice President and Chief Technical Officer. From December 1986 to March 1990, he served Paco Research Corp. as Manager – Product Development. From April 1983 to December 1986, he served Key Pharmaceuticals, Inc. as Senior Research Engineer where he helped develop some of the most successful transdermal products of that era.

Michael Price joined Noven in November 2007 and serves as Vice President and Chief Financial Officer. He is a CPA with over 25 years of experience as a financial executive. From 1992 to 2006, he served as Vice President, Chief Financial Officer, Treasurer and Secretary for Bentley Pharmaceuticals, Inc., a NYSE listed specialty pharmaceuticals company. He also acted as a member of that company’s board of directors for nine years. Earlier in his career, he served as a senior executive with Carr Financial Group, and as Vice President - Finance with Premiere Group, Inc.

Steven Dinh joined Noven in June 2008 and serves as Vice President and Chief Scientific Officer. He has more than 25 years' experience in drug delivery, biotechnology, pharmaceutical development and polymer engineering. Prior to joining Noven, he served as Vice President of Research and Technology Development and Co-Chair – Office of the President for Emisphere Technologies. Earlier, he served as Chief Scientific Officer and Vice President of Research & Development for Lavipharm Laboratories, and before that, he held several senior-level R&D positions at Novartis Pharmaceuticals Corporation and Ciba-Geigy. Mr. Dinh has co-authored three books, over 30 articles for scientific publications, and more than 100 abstracts. He holds a Doctor of Science degree from the Massachusetts Institute of Technology, a Masters of Science degree from Cornell University, and a Bachelor of Engineering degree from Cooper Union.

Anthony Venditti joined Noven in June 2008 and serves as Vice President – Marketing & Sales. He has over 20 years of pharmaceutical marketing and sales experience. Prior to joining Noven, he served as Vice President and head of the U.S. Neuroscience division for Novartis Pharmaceuticals Corporation, where he was responsible for marketing, sales and new product operations for the central nervous system (CNS) portfolio in the U.S. Before that, he served Novartis in a number of senior executive positions, with responsibility for marketing, sales, business analysis, strategic planning and new product commercialization, including key roles in the launch of several new products.

Carolyn Donaldson is the Vice President of Human Resources for Miami-based Noven Pharmaceuticals, Inc., a leading developer of transdermal drug delivery technologies and products. Carolyn's professional and community contributions include leadership roles in the following organizations: United Way of Miami Dade County (Board), Goodwill Industries of South Florida (Board) and Greater Miami Chamber of Commerce (Board). She holds a Master's Degree in Human Resources Management from Florida International University as well as awards for her contribution to the Human Resources profession as recipient of the Life Time Achievement Award from the Greater Miami Society for Human Resources Management (GMSHRM) and the South Florida Business Journal - Excellence in Human Resources Award. With 25+ years in the medical device and pharmaceutical industry Carolyn remains committed to raising the level of awareness among women of opportunities in the areas of science, engineering and biomedical technology.

Joseph Jones has been with Noven since January 2001 and serves as Vice President – Corporate Affairs. He is principally responsible for analyst, investor and corporate communications as well as the company's governmental affairs function. Prior to joining Noven, he was President of SHD Strategic, L.C., a corporate communications consulting firm, and before that he served as Vice President, Investor Relations and Government Affairs for IVAX Corporation. Prior to joining IVAX, he was a partner in the corporate securities department of the law firm of Steel Hector & Davis.

Pavan Handa joined Noven in July 2002 and serves as Vice President – Business Development and Alliance Management. He has over twenty years of pharmaceutical industry, business development, and strategic alliance experience in structuring and negotiating over 50 agreements involving licensing, acquisitions, investments, and strategic collaborations. Prior to joining Noven, he served as Senior Vice President, Business Development and Portfolio Management for Pharmacologics LLC, Director of Business Development and Marketing for Enzon Pharmaceuticals Inc., and Manager of Biomedical Business Development for Union Carbide Corporation.

Peter Amanatides joined Noven in September 2008 and serves as Vice President – Quality Assurance & Quality Control. He has over 20 years of diverse pharmaceutical and biotechnology industry experience. Prior to joining Noven, he served in several senior quality roles at DSM Pharmaceuticals, Inc., most recently as Senior Director – Quality Operations & Regulatory Affairs, the senior-most quality officer at DSM Pharmaceuticals. Prior to his career at DSM, he was Director of Quality Systems at Celera Genomics. Mr. Amanatides holds a Master of Science degree in biotechnology and molecular biology from Hood College and a Bachelor of Science Degree in biology from Regents College.

Richard Gilbert joined Noven in December 2004 and serves as Vice President – Operations. He has over 22 years of experience in operations and manufacturing. Prior to joining Noven, he served as Vice President, Manufacturing Operations, at ConvaTec (a Bristol-Myers Squibb Company). Prior to ConvaTec, he held various senior roles at London International Group, LLC, The Tensar Corporation, and Richmond Technology.

Neil Jones has been with Noven since February 1997 and, since November 2000, has served as Vice President, Marketing and Sales. From 1981 through 1997, he served Ciba-Geigy Corporation in a variety of sales and marketing positions, most recently as Executive Director of Marketing.

Jeff Mihm has been with Noven since 2003 and serves as Vice President and General Counsel. Prior to Noven, he served as Senior Corporate Counsel to Panamerican Beverages, Inc., the world's third largest Coca-Cola bottler at the time, and previously was a partner in the corporate securities department of the law firm of Steel Hector & Davis.

Katherine M. Cooley (Kate), MBA, is the founder and President of Market Analytics Group. She is the former Marketing Science and Research department head for Noven Pharmaceuticals. Kate is a top tier MBA and Pacesetter recipient from The Ohio State University as well as a former NASA engineer with rigorous knowledge of quantitative modeling methods and their application in the development of actionable solutions for current business issues. Kate founded the practice with the belief that there was a great opportunity to better exploit pharmaceutical brand insights via a well integrated marriage of secondary analytics and primary research. She is the guiding influence behind Market Analytics Group and her leadership sets a determined path for insuring customized care and unsurpassed client satisfaction.

Robert Strauss is Chairman of the Board of Directors, and has been President and Chief Executive Officer and a Director of Noven since December 1997. From March 1997 to July 1997, he served as President and Chief Operating Officer and a Director of IVAX Corporation. From 1983 to 1997, he served in various executive positions with Cordis Corporation, most recently as its Chairman of the Board, President and Chief Executive Officer.

Mr. Braginsky is President and Chief Executive Officer of Atropos Technology Inc. (consulting and venture capital) and Chairman of Digilab LLC (molecular spectroscopy). From 1970 through 1999, Mr. Braginsky served Olympus America, Inc. in a variety of roles, most recently as President and Chief Operating Officer. Mr. Braginsky serves on the board of directors of Mediscience (optical biopsy development), Diomed Holdings (laser technology), Geneva Acquisition Corporation (acquisitions) and Electro-Optical Sciences, Inc. (surgical and medical instruments).

Mr. Granadillo was employed by Eli Lilly and Company (pharmaceuticals) from 1970 until 2004. From 1998 to 2004, he served as Eli Lilly’s Senior Vice President overseeing manufacturing, quality and human resources and from 1993 to 1998, he served as Vice President of Human Resources. Mr. Granadillo serves on the board of directors of Nile Therapeutics, Inc. (biopharmaceuticals) and Haemonetics Corporation (medical devices).

Mr. Satow was appointed to Noven's Board of Directors in August 2007 upon the closing of Noven's acquisition of JDS Pharmaceuticals, LLC. Mr. Satow was JDS's co-founder and served as its Chief Executive Officer from inception in August 2004 through completion of the acquisition. After 15 years with Pfizer and three years as Vice President and General Manager of the Carter Wallace pharmaceutical business, Mr. Satow served as Executive Vice President of Forest Laboratories and President of its Forest Pharmaceuticals subsidiary. He established the marketing and sales departments at Forest, which he led for 14 years through the launch of Forest's highly-successful antidepressant Celexa .